Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Stephen B. Hanauer

TitleEmeritus/Emerita
InstitutionUniversity of Chicago
DepartmentMedicine
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2019 Nov 21. PMID: 31755070.
      View in: PubMed
    2. Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W. Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. J Crohns Colitis. 2019 Sep 19; 13(9):1227-1233. PMID: 30726897.
      View in: PubMed
    3. Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2019 Sep; 17(3):420-433. PMID: 31352659.
      View in: PubMed
    4. Taft TH, Quinton S, Tomasino K, Craven M, Guadagnoli L, Bedell A, Hanauer S. Letter to the Editor: Patients With Inflammatory Bowel Disease Demonstrate an Inherent Lack of Psychopathology. Inflamm Bowel Dis. 2019 Aug 20; 25(9):e114. PMID: 30989208.
      View in: PubMed
    5. Taft TH, Bedell A, Craven MR, Guadagnoli L, Quinton S, Hanauer SB. Initial Assessment of Post-traumatic Stress in a US Cohort of Inflammatory Bowel Disease Patients. Inflamm Bowel Dis. 2019 Aug 20; 25(9):1577-1585. PMID: 30840762.
      View in: PubMed
    6. Hanauer SB, Schreiber S. Perspectives of Clinicians in the United States and Europe on Monitoring Levels of Biologic Agents in Patients Receiving Biologic Therapies for Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 Aug; 17(9):1718-1723. PMID: 31255806.
      View in: PubMed
    7. Linson EA, Hanauer SB. More Than a Tumor Marker…A Potential Role for Alpha-Feto Protein in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 06 18; 25(7):1271-1276. PMID: 30624658.
      View in: PubMed
    8. Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S. IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2019 Jun 03. PMID: 31158271.
      View in: PubMed
    9. Gupta N, Hanauer SB. Too Soon to Discard 5-ASAs? Am J Gastroenterol. 2019 Mar; 114(3):534-535. PMID: 30694871.
      View in: PubMed
    10. Butin-Israeli V, Bui TM, Wiesolek HL, Mascarenhas L, Lee JJ, Mehl LC, Knutson KR, Adam SA, Goldman RD, Beyder A, Wiesmuller L, Hanauer SB, Sumagin R. Neutrophil-induced genomic instability impedes resolution of inflammation and wound healing. J Clin Invest. 2019 Feb 01; 129(2):712-726. PMID: 30640176.
      View in: PubMed
    11. Burns JA, Weiner AB, Catalona WJ, Li EV, Schaeffer EM, Hanauer SB, Strong S, Burns J, Hussain MHA, Kundu SD. Inflammatory Bowel Disease and the Risk of Prostate Cancer. Eur Urol. 2019 05; 75(5):846-852. PMID: 30528221.
      View in: PubMed
    12. Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 Jul; 17(8):1525-1532.e1. PMID: 30267864.
      View in: PubMed
    13. Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 01; 17(1):139-147. PMID: 30012431.
      View in: PubMed
    14. Hanauer SB, Sandborn WJ, Lichtenstein GR. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42. PMID: 30195449.
      View in: PubMed
    15. Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 07; 48(1):65-77. PMID: 29797519.
      View in: PubMed
    16. Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297. PMID: 29506124.
      View in: PubMed
    17. Krugliak Cleveland N, Ollech JE, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Hurst R, Rubin DT. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol. 2019 01; 17(1):205-206. PMID: 29751167.
      View in: PubMed
    18. Calabrese E, Kucharzik T, Maaser C, Maconi G, Strobel D, Wilson SR, Zorzi F, Novak KL, Bruining DH, Iacucci M, Watanabe M, Lolli E, Chiaramonte C, Hanauer SB, Panaccione R, Pallone F, Ghosh S, Monteleone G. Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study. Inflamm Bowel Dis. 2018 Apr 28. PMID: 29718450.
      View in: PubMed
    19. Hanauer SB. Improving IBD Care: A Personalized Approach to Management. Gastroenterol Hepatol (N Y). 2018 Mar; 14(3):1-20. PMID: 29991932.
      View in: PubMed
    20. Friedman AB, Brown SJ, Bampton P, Barclay ML, Chung A, Macrae FA, McKenzie J, Reynolds J, Gibson PR, Hanauer SB, Sparrow MP. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018 Apr; 47(8):1092-1102. PMID: 29468701.
      View in: PubMed
    21. Papamichael K, Osterman MT, Siegel CA, Melmed GY, Dubinsky MC, Colombel JF, Hanauer SB, Cheifetz AS. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? Gastroenterology. 2018 03; 154(4):1201-1202. PMID: 29432749.
      View in: PubMed
    22. Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 05; 154(6):1660-1671. PMID: 29409871.
      View in: PubMed
    23. Hanauer SB. A Never Ending STORI. Clin Gastroenterol Hepatol. 2018 07; 16(7):1034-1036. PMID: 29391270.
      View in: PubMed
    24. Krugliak Cleveland N, Huo D, Sadiq F, Sofia MA, Marks J, Cohen RD, Hanauer SB, Turner J, Hart J, Rubin DT. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309. PMID: 29307473.
      View in: PubMed
    25. Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228. PMID: 29159817.
      View in: PubMed
    26. Hanauer SB. Targeting Crohn's disease. Lancet. 2018 12 23; 390(10114):2742-2744. PMID: 29096947.
      View in: PubMed
    27. Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease? ACG Case Rep J. 2017; 4:e112. PMID: 29043290.
      View in: PubMed
    28. Pekow J, Hutchison AL, Meckel K, Harrington K, Deng Z, Talasila N, Rubin DT, Hanauer SB, Hurst R, Umanskiy K, Fichera A, Hart J, Dinner AR, Bissonnette M. miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling. Inflamm Bowel Dis. 2017 08; 23(8):1328-1337. PMID: 28594651.
      View in: PubMed
    29. Akhuemonkhan E, Parian A, Miller K, Hanauer S, Hutfless S. Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010-2014. BMJ Open Gastroenterol. 2017; 4(1):e000155. PMID: 28944071.
      View in: PubMed
    30. Chang S, Hanauer S. Optimizing pharmacologic management of inflammatory bowel disease. Expert Rev Clin Pharmacol. 2017 Jun; 10(6):595-607. PMID: 28475384.
      View in: PubMed
    31. Hanauer SB. Combination Therapy for Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2017 May; 13(5):296-298. PMID: 28656027.
      View in: PubMed
    32. Hanauer SB. Targeting interleukin 23 for Crohn's disease: finding the right drug for the right patient. Lancet. 2017 04 29; 389(10080):1671-1672. PMID: 28411871.
      View in: PubMed
    33. Grosen A, Kelsen J, Hvas CL, Bellaguarda E, Hanauer SB. The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure. Inflamm Bowel Dis. 2017 04; 23(4):561-569. PMID: 28267049.
      View in: PubMed
    34. Bhattacharyya S, Shumard T, Xie H, Dodda A, Varady KA, Feferman L, Halline AG, Goldstein JL, Hanauer SB, Tobacman JK. A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity. Nutr Healthy Aging. 2017 Mar 31; 4(2):181-192. PMID: 28447072.
      View in: PubMed
    35. Chang S, Hanauer S. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2017 Mar; 15(1):53-70. PMID: 28164249.
      View in: PubMed
    36. Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. Clin Gastroenterol Hepatol. 2017 Oct; 15(10):1557-1564.e1. PMID: 28238954.
      View in: PubMed
    37. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 11 17; 375(20):1946-1960. PMID: 27959607.
      View in: PubMed
    38. Hanauer SB. Vitamin D Levels and Outcomes in Inflammatory Bowel Disease-Which is the Chicken and Which is the Egg? Clin Gastroenterol Hepatol. 2017 02; 15(2):247-248. PMID: 27825894.
      View in: PubMed
    39. Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 11; 22(11):2711-2723. PMID: 27585411.
      View in: PubMed
    40. Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. Development of an index to define overall disease severity in IBD. Gut. 2018 02; 67(2):244-254. PMID: 27780886.
      View in: PubMed
    41. Liu K, Prasad MA, Lo A, Bellaguarda E, Strong S, Hanauer SB. Primary Adenocarcinoma of an Ileostomy in Crohn's Disease. ACG Case Rep J. 2016 Jul; 3(4):e112. PMID: 27622191.
      View in: PubMed
    42. Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80. PMID: 27400222.
      View in: PubMed
    43. Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870. PMID: 27372735.
      View in: PubMed
    44. Meckel K, Li YC, Lim J, Kocherginsky M, Weber C, Almoghrabi A, Chen X, Kaboff A, Sadiq F, Hanauer SB, Cohen RD, Kwon J, Rubin DT, Hanan I, Sakuraba A, Yen E, Bissonnette M, Pekow J. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20. PMID: 27281309.
      View in: PubMed
    45. Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016 May 05; 374(18):1754-62. PMID: 27144850.
      View in: PubMed
    46. Calabrese E, Maaser C, Zorzi F, Kannengiesser K, Hanauer SB, Bruining DH, Iacucci M, Maconi G, Novak KL, Panaccione R, Strobel D, Wilson SR, Watanabe M, Pallone F, Ghosh S. Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts. Inflamm Bowel Dis. 2016 May; 22(5):1168-83. PMID: 26958988.
      View in: PubMed
    47. Trivedi I, Holl JL, Hanauer S, Keefer L. Integrating Adolescents and Young Adults into Adult-Centered Care for IBD. Curr Gastroenterol Rep. 2016 May; 18(5):21. PMID: 27086002.
      View in: PubMed
    48. Hanauer SB. Oral or Topical 5-ASA in Ulcerative Colitis. Dig Dis. 2016; 34(1-2):122-4. PMID: 26982709.
      View in: PubMed
    49. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578. PMID: 26946343.
      View in: PubMed
    50. Krugliak Cleveland N, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Rubin DT. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7. PMID: 26658214.
      View in: PubMed
    51. Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao LL, Sands B, Hanauer S, Feagan B, Targan S, Ghosh S, de Villiers W, Colombel JF, Lee S, Desreumaux P, Loftus E, Vermeire S, Rutgeerts P. O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNa: UNITI-1. Inflamm Bowel Dis. 2016 Mar; 22 Suppl 1:S1. PMID: 26849718.
      View in: PubMed
    52. D'Haens G, Bressler B, Danese S, Gibson P, Hanauer SB, Sandborn W. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):638-9. PMID: 26850690.
      View in: PubMed
    53. Trivedi I, Raj R, Hanauer S. Hyperacute Methotrexate Pneumonitis in a Patient With Crohn's Disease. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):A29-30. PMID: 26592712.
      View in: PubMed
    54. Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf. 2015; 14(12):1915-34. PMID: 26559664.
      View in: PubMed
    55. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38. PMID: 26303131.
      View in: PubMed
    56. Melmed GY, Pandak WM, Casey K, Abraham B, Valentine J, Schwartz D, Awais D, Bassan I, Lichtiger S, Sands B, Hanauer S, Richards R, Oikonomou I, Parekh N, Targan S, Johnson K, Hariri R, Fischkoff S. Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study. Inflamm Bowel Dis. 2015 Aug; 21(8):1809-16. PMID: 25985246.
      View in: PubMed
    57. Hanauer SB. Reply: To PMID 25311382. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2384-5. PMID: 26215841.
      View in: PubMed
    58. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17. PMID: 26071941.
      View in: PubMed
    59. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40. PMID: 25989338.
      View in: PubMed
    60. Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA, Sandborn WJ. The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015 Aug; 9(8):607-16. PMID: 25956538.
      View in: PubMed
    61. Lichtenstein GR, Hanauer SB, Sandborn WJ. Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2015 Mar; 11(3 Suppl 1):1-16. PMID: 26491415.
      View in: PubMed
    62. Hanauer SB. ACG presidential introduction. Am J Gastroenterol. 2015 Jan; 110(1):4-5. PMID: 25567163.
      View in: PubMed
    63. Ananthakrishnan AN, Hanauer SB. The Holy Grail, or only half way there? Gastroenterology. 2015 Jan; 148(1):8-10. PMID: 25451664.
      View in: PubMed
    64. Hanauer SB. Heading back to the trough (levels of biologics in IBD). Clin Gastroenterol Hepatol. 2015 Mar; 13(3):548-51. PMID: 25311382.
      View in: PubMed
    65. Stein AC, Rubin DT, Hanauer SB, Cohen RD. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8. PMID: 25171509.
      View in: PubMed
    66. Ford AC, Luthra P, Hanauer SB, Travis SP, Harris MS, Reinisch W. Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):1981-90. PMID: 25218669.
      View in: PubMed
    67. Maranville JC, Micic D, Hanauer SB, Di Rienzo A, Kupfer SS. In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. J Crohns Colitis. 2014 Nov; 8(11):1539-47. PMID: 25052346.
      View in: PubMed
    68. Feagan BG, Colombel JF, Hanauer SB, Parikh A, Rutgeerts P, Sandborn WJ, Sands BE. Comment on 'anti-adhesion therapies and the rule of 3 for rare events'. Am J Gastroenterol. 2014 Jul; 109(7):1083-4. PMID: 24989100.
      View in: PubMed
    69. Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 Sep; 147(3):618-627.e3. PMID: 24859203.
      View in: PubMed
    70. Ho IK, Cash BD, Cohen H, Hanauer SB, Inkster M, Johnson DA, Maher MM, Rex DK, Saad A, Singh A, Rehani MM, Quigley EM. Radiation exposure in gastroenterology: improving patient and staff protection. Am J Gastroenterol. 2014 Aug; 109(8):1180-94. PMID: 24842339.
      View in: PubMed
    71. Reinisch W, Travis S, Hanauer S, Wang H, Shara N, Harris MS. AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study. Inflamm Bowel Dis. 2014 May; 20(5):872-81. PMID: 24694794.
      View in: PubMed
    72. Sandborn WJ, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis. 2014 Sep; 8(9):927-35. PMID: 24713173.
      View in: PubMed
    73. Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, Rutgeerts P, Vermeire S. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014 Nov; 63(11):1721-7. PMID: 24474383.
      View in: PubMed
    74. Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec; 145(6):1464-78.e1-5. PMID: 24267475.
      View in: PubMed
    75. Hanauer SB. Still in pursuit. Gastroenterology. 2014 Jan; 146(1):13-5. PMID: 24287301.
      View in: PubMed
    76. Dassopoulos T, Dubinsky MC, Bentsen JL, Martin CF, Galanko JA, Seidman EG, Sandler RS, Hanauer SB. Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease. Aliment Pharmacol Ther. 2014 Jan; 39(2):163-75. PMID: 24237037.
      View in: PubMed
    77. Hanauer SB, Kirsner JB. Comparing guidelines for the treatment of inflammatory bowel disease. Dig Dis. 2013; 31(3-4):360-2. PMID: 24246988.
      View in: PubMed
    78. Sakuraba A, Annunziata ML, Cohen RD, Hanauer SB, Rubin DT. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83. PMID: 24132161.
      View in: PubMed
    79. Hanauer SB. Dissecting diverticulosis database dilemmas. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1525-6. PMID: 24157249.
      View in: PubMed
    80. Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin Gastroenterol Hepatol. 2015 Jun; 13(6):1042-50.e2. PMID: 24036054.
      View in: PubMed
    81. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369(8):699-710. PMID: 23964932.
      View in: PubMed
    82. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 Aug 22; 369(8):711-21. PMID: 23964933.
      View in: PubMed
    83. Liu W, Chen Y, Golan MA, Annunziata ML, Du J, Dougherty U, Kong J, Musch M, Huang Y, Pekow J, Zheng C, Bissonnette M, Hanauer SB, Li YC. Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest. 2013 Sep; 123(9):3983-96. PMID: 23945234.
      View in: PubMed
    84. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Schnell P, Bernhardt CA, Mary JY, Sandborn WJ. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013 Nov; 145(5):987-95. PMID: 23891974.
      View in: PubMed
    85. Rubin DT, Huo D, Kinnucan JA, Sedrak MS, McCullom NE, Bunnag AP, Raun-Royer EP, Cohen RD, Hanauer SB, Hart J, Turner JR. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4. PMID: 23872237.
      View in: PubMed
    86. Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N, Harnett MD, Hanauer SB. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease. Aliment Pharmacol Ther. 2013 Aug; 38(3):255-63. PMID: 23730956.
      View in: PubMed
    87. Herfarth HH, Katz JA, Hanauer SB, Sandborn WJ, Loftus EV, Sands BE, Galanko JA, Walkup D, Isaacs KL, Martin CF, Sandler RS, Sartor RB. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013 Apr; 19(5):1073-9. PMID: 23511031.
      View in: PubMed
    88. Pekow J, Dougherty U, Huang Y, Gometz E, Nathanson J, Cohen G, Levy S, Kocherginsky M, Venu N, Westerhoff M, Hart J, Noffsinger AE, Hanauer SB, Hurst RD, Fichera A, Joseph LJ, Liu Q, Bissonnette M. Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions. Inflamm Bowel Dis. 2013 Mar; 19(3):461-70. PMID: 23388545.
      View in: PubMed
    89. Melmed GY, Siegel CA, Spiegel BM, Allen JI, Cima R, Colombel JF, Dassopoulos T, Denson LA, Dudley-Brown S, Garb A, Hanauer SB, Kappelman MD, Lewis JD, Lynch I, Moynihan A, Rubin DT, Sartor RB, Schwartz RM, Wolf DC, Ullman TA. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013 Mar; 19(3):662-8. PMID: 23388547.
      View in: PubMed
    90. Sakuraba A, Keyashian K, Correia C, Melek J, Cohen RD, Hanauer SB, Rubin DT. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6. PMID: 23429449.
      View in: PubMed
    91. Mayer L, Pandak WM, Melmed GY, Hanauer SB, Johnson K, Payne D, Faleck H, Hariri RJ, Fischkoff SA. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study. Inflamm Bowel Dis. 2013 Mar-Apr; 19(4):754-60. PMID: 23429460.
      View in: PubMed
    92. Hoentjen F, Seinen ML, Hanauer SB, de Boer NK, Rubin DT, Bouma G, Harrell LE, van Bodegraven AA. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9. PMID: 22605661.
      View in: PubMed
    93. Kinnucan JA, Hanauer SB. Reassessing the risks and benefits of thiopurines in Crohn's disease. Clin Gastroenterol Hepatol. 2013 Apr; 11(4):395-7. PMID: 23333707.
      View in: PubMed
    94. Hoentjen F, Hanauer SB, Hart J, Rubin DT. Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-enteritis after colectomy. J Clin Gastroenterol. 2013 Jan; 47(1):52-7. PMID: 22858512.
      View in: PubMed
    95. Hanauer SB, Rubin DT. Joseph Barnett Kirsner, MD, PhD. Dig Dis Sci. 2012 Nov; 57(11):2722-4. PMID: 23236606.
      View in: PubMed
    96. Lichtenstein GR, Hanauer SB, Sandborn WJ. Risk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's Disease. Gastroenterol Hepatol (N Y). 2012 Nov; 8(11 Suppl 8):1-20. PMID: 24847181.
      View in: PubMed
    97. Hanauer SB, Rubin DT. In memoriam. Inflamm Bowel Dis. 2012 Nov; 18(11):2001-3. PMID: 23070951.
      View in: PubMed
    98. Hanauer SB, Rubin DT. Joseph Barnett Kirsner, MD, PhD. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1181-2. PMID: 23084570.
      View in: PubMed
    99. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012 Oct 18; 367(16):1519-28. PMID: 23075178.
      View in: PubMed
    100. Calabrese E, Hanauer SB. Reply to Dr Kountouras et al.'s letter. J Crohns Colitis. 2013 Jul; 7(6):515. PMID: 23062329.
      View in: PubMed
    101. Hanauer SB, Rubin D. Joseph Barnett Kirsner, MD, PhD. Gastrointest Endosc. 2012 Oct; 76(4):730-2. PMID: 22985640.
      View in: PubMed
    102. Hanauer SB, Rubin DT. In memoriam: Dr Joseph Barnett Kirsner. Gut. 2012 Nov; 61(11):1636-7. PMID: 22976043.
      View in: PubMed
    103. Hanauer SB. What to take from TREAT? Am J Gastroenterol. 2012 Sep; 107(9):1423-5. PMID: 22951879.
      View in: PubMed
    104. Pekow J, Li YC, Hanauer SB. Association between higher predicted serum vitamin D levels and reduced incidence of inflammatory bowel diseases. Gastroenterology. 2012 Sep; 143(3):e28. PMID: 22841731.
      View in: PubMed
    105. Hanauer SB, Kirsner JB. Treat the patient or treat the disease? Dig Dis. 2012; 30(4):400-3. PMID: 22796805.
      View in: PubMed
    106. Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut. 2013 Sep; 62(9):1288-94. PMID: 22760005.
      View in: PubMed
    107. Kaufman AB, Hanauer SB. Commentary: pre-operative use of anti-TNF-a agents and the risk of post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther. 2012 Jul; 36(2):199-200; discussion 200. PMID: 22703456.
      View in: PubMed
    108. Hanauer SB. Disease modification in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012 Sep; 10(9):954-5. PMID: 22728318.
      View in: PubMed
    109. Hoentjen F, Colwell JC, Hanauer SB. Complications of peristomal recurrence of Crohn's disease: a case report and a review of literature. J Wound Ostomy Continence Nurs. 2012 May-Jun; 39(3):297-301. PMID: 22552106.
      View in: PubMed
    110. Keyashian K, Annunziata ML, Sakuraba A, Hanauer S. Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012 May; 8(4):303-5. PMID: 22607175.
      View in: PubMed
    111. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB. Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology. 2012 Jul; 143(1):62-69.e4. PMID: 22504093.
      View in: PubMed
    112. Harrell L, Wang Y, Antonopoulos D, Young V, Lichtenstein L, Huang Y, Hanauer S, Chang E. Standard colonic lavage alters the natural state of mucosal-associated microbiota in the human colon. PLoS One. 2012; 7(2):e32545. PMID: 22389708.
      View in: PubMed
    113. Leung Y, Kaplan GG, Rioux KP, Hubbard J, Kamhawi S, Stasiak L, Cohen RD, Devlin SM, Panaccione R, Hanauer SB, Rubin DT. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32. PMID: 22311366.
      View in: PubMed
    114. Louis E, Baumgart DC, Ghosh S, Gomollón F, Hanauer S, Hart A, Irving P. What changes in inflammatory bowel disease management can be implemented today? J Crohns Colitis. 2012 Feb; 6 Suppl 2:S260-7. PMID: 22463933.
      View in: PubMed
    115. Annunziata ML, Hanauer S. Can we treat ulcerative colitis with nutritional supplements? Aliment Pharmacol Ther. 2012 Feb; 35(4):485; author reply 486-7. PMID: 22248423.
      View in: PubMed
    116. Calabrese E, Yanai H, Shuster D, Rubin DT, Hanauer SB. Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohns Colitis. 2012 Aug; 6(7):756-62. PMID: 22398093.
      View in: PubMed
    117. Hoentjen F, Hanauer SB, de Boer NK, Rubin DT. Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction. Dig Dis Sci. 2012 Jan; 57(1):250-3. PMID: 22147254.
      View in: PubMed
    118. Ford AC, Khan KJ, Sandborn WJ, Hanauer SB, Moayyedi P. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012 May; 10(5):513-9. PMID: 22083024.
      View in: PubMed
    119. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, Marteau PR, Reinisch W, Sands BE, Yacyshyn BR, Bernhardt CA, Mary JY, Sandborn WJ. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut. 2012 Apr; 61(4):535-42. PMID: 21997563.
      View in: PubMed
    120. Hoentjen F, Sakuraba A, Hanauer S. Update on the management of ulcerative colitis. Curr Gastroenterol Rep. 2011 Oct; 13(5):475-85. PMID: 21789495.
      View in: PubMed
    121. Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Aliment Pharmacol Ther. 2011 Oct; 34(7):747-56. PMID: 21848857.
      View in: PubMed
    122. Annunziata ML, Hanauer SB. Calcineurin inhibition in severe ulcerative colitis: lost in translation? Inflamm Bowel Dis. 2012 May; 18(5):809-11. PMID: 21837776.
      View in: PubMed
    123. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 Oct; 141(4):1194-201. PMID: 21723220.
      View in: PubMed
    124. Kamm MA, Hanauer SB, Panaccione R, Colombel JF, Sandborn WJ, Pollack PF, Zhou Q, Robinson AM. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011 Aug; 34(3):306-17. PMID: 21645018.
      View in: PubMed
    125. Pekow JR, Dougherty U, Mustafi R, Zhu H, Kocherginsky M, Rubin DT, Hanauer SB, Hart J, Chang EB, Fichera A, Joseph LJ, Bissonnette M. miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis. 2012 Jan; 18(1):94-100. PMID: 21557394.
      View in: PubMed
    126. Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, Johanns J, Colombel JF, Present D, Sands BE. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2012 Feb; 18(2):201-11. PMID: 21484965.
      View in: PubMed
    127. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011 Apr; 106 Suppl 1:S2-25; quiz S26. PMID: 21472012.
      View in: PubMed
    128. Kavanaugh AF, Mayer LF, Cush JJ, Hanauer SB. Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's disease. Am J Med. 2011 Apr; 124(4 Suppl):e1-18. PMID: 21531240.
      View in: PubMed
    129. Cohen RD, Lewis JR, Turner H, Harrell LE, Hanauer SB, Rubin DT. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6. PMID: 21456032.
      View in: PubMed
    130. Feagan BG, Hanauer SB, Coteur G, Schreiber S. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther. 2011 May; 33(10):1143-51. PMID: 21443536.
      View in: PubMed
    131. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011 Apr; 106(4):685-98. PMID: 21427713.
      View in: PubMed
    132. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr; 106(4):644-59, quiz 660. PMID: 21407183.
      View in: PubMed
    133. Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm Bowel Dis. 2011 Nov; 17(11):2366-91. PMID: 21337669.
      View in: PubMed
    134. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun; 60(6):780-7. PMID: 21209123.
      View in: PubMed
    135. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010 Dec 08; (12):CD008870. PMID: 21154400.
      View in: PubMed
    136. Hanauer SB, Kornbluth AA, Messick J, Rubin DT, Sandborn WJ, Sands BE. Clinical scenarios in IBD: optimizing the use of conventional and biologic agents. Inflamm Bowel Dis. 2010 Dec; 16 Suppl 1:S1-11. PMID: 21104734.
      View in: PubMed
    137. Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93. PMID: 21083671.
      View in: PubMed
    138. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Watermayer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213. PMID: 21045814.
      View in: PubMed
    139. Calabrese E, Hanauer SB. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease. J Crohns Colitis. 2011 Feb; 5(1):48-53. PMID: 21272804.
      View in: PubMed
    140. Hanauer SB. The role of biologics in ulcerative colitis. Dig Dis. 2010; 28(3):497-500. PMID: 20926878.
      View in: PubMed
    141. Pekow JR, Hetzel JT, Rothe JA, Hanauer SB, Turner JR, Hart J, Noffsinger A, Huo D, Rubin DT. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis. 2010 Aug; 16(8):1352-6. PMID: 20027656.
      View in: PubMed
    142. Hanauer SB, Hommes DW. Inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul; 6(4):499-500. PMID: 20594118.
      View in: PubMed
    143. Hanauer SB. Ashes to ashes. Nat Rev Gastroenterol Hepatol. 2010 Jun; 7(6):299. PMID: 20523348.
      View in: PubMed
    144. Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010 Aug; 32(3):384-93. PMID: 20491747.
      View in: PubMed
    145. Lodolce JP, Kolodziej LE, Rhee L, Kariuki SN, Franek BS, McGreal NM, Logsdon MF, Bartulis SJ, Perera MA, Ellis NA, Adams EJ, Hanauer SB, Jolly M, Niewold TB, Boone DL. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J Immunol. 2010 Jun 15; 184(12):7001-9. PMID: 20483768.
      View in: PubMed
    146. Hanauer SB. Penultimate. Nat Rev Gastroenterol Hepatol. 2010 May; 7(5):237. PMID: 20442729.
      View in: PubMed
    147. Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol. 2010 Aug; 8(8):696-702.e1. PMID: 20363366.
      View in: PubMed
    148. Hanauer SB. Another vacation, another medical 'crisis'. Nat Rev Gastroenterol Hepatol. 2010 Apr; 7(4):179. PMID: 20376088.
      View in: PubMed
    149. Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9. PMID: 19714757.
      View in: PubMed
    150. Hanauer SB. Devolving therapeutic pyramids. Nat Rev Gastroenterol Hepatol. 2010 Mar; 7(3):119-20. PMID: 20203676.
      View in: PubMed
    151. Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010 Jul; 8(7):600-9. PMID: 20117244.
      View in: PubMed
    152. Hanauer SB. The expanding role of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010 Feb; 7(2):63-4. PMID: 20134483.
      View in: PubMed
    153. Hanauer SB. A poor view from specialty silos. Nat Rev Gastroenterol Hepatol. 2010 Jan; 7(1):1-2. PMID: 20051965.
      View in: PubMed
    154. Sparrow MP, Irving PM, Hanauer SB. Optimizing conventional therapies for inflammatory bowel disease. Curr Gastroenterol Rep. 2009 Dec; 11(6):496-503. PMID: 19903426.
      View in: PubMed
    155. Hanauer SB. Indecent exposures. Nat Rev Gastroenterol Hepatol. 2009 Dec; 6(12):685. PMID: 19946299.
      View in: PubMed
    156. Hanauer SB. Medical management of Crohn's disease: treatment algorithms 2009. Dig Dis. 2009; 27(4):536-41. PMID: 19897971.
      View in: PubMed
    157. Hanauer SB. Great (cultural) expectations. Nat Rev Gastroenterol Hepatol. 2009 Nov; 6(11):623. PMID: 19881511.
      View in: PubMed
    158. Hanauer SB. The wrong end of the scope. Nat Rev Gastroenterol Hepatol. 2009 Oct; 6(10):559. PMID: 19789569.
      View in: PubMed
    159. Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis. 2009 Oct; 15(10):1570-82. PMID: 19309716.
      View in: PubMed
    160. Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009 Dec; 137(6):1934-43.e1-3. PMID: 19766640.
      View in: PubMed
    161. Hanauer S. Don't miss the forest for the trees. Inflamm Bowel Dis. 2009 Sep; 15(9):1397-8. PMID: 19591133.
      View in: PubMed
    162. Hanauer SB. Exploring the controversial themes of IBD. Inflamm Bowel Dis. 2009 Sep; 15 Suppl 1:S1-10. PMID: 19693963.
      View in: PubMed
    163. Hanauer SB. Addicted to acid suppression. Nat Rev Gastroenterol Hepatol. 2009 Sep; 6(9):497. PMID: 19713979.
      View in: PubMed
    164. Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn WJ. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7. PMID: 19408340.
      View in: PubMed
    165. Hanauer SB. Quid pro quo and the pharmascolds. Nat Rev Gastroenterol Hepatol. 2009 Aug; 6(8):437. PMID: 19654595.
      View in: PubMed
    166. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009 Oct; 137(4):1250-60; quiz 1520. PMID: 19596014.
      View in: PubMed
    167. Hanauer SB. The burdens of digestive diseases. Nat Rev Gastroenterol Hepatol. 2009 Jul; 6(7):377. PMID: 19575019.
      View in: PubMed
    168. Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol. 2009 Aug; 104(8):2089-96. PMID: 19568226.
      View in: PubMed
    169. Leung Y, Hanauer SB. Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow? Gastroenterol Clin Biol. 2009 Jun; 33 Suppl 3:S202-8. PMID: 20117343.
      View in: PubMed
    170. Hanauer SB, Present DH, Rubin DT. Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. Gastroenterol Hepatol (N Y). 2009 Jun; 5(6 Suppl):4-16. PMID: 20574506.
      View in: PubMed
    171. Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009 Jun; 15(6):829-36. PMID: 19130617.
      View in: PubMed
    172. Yun L, Hanauer S. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2009 Jun; 3(3):235-48. PMID: 19485806.
      View in: PubMed
    173. Hanauer SB. Keep your cool: burn calories. Nat Rev Gastroenterol Hepatol. 2009 Jun; 6(6):315. PMID: 19494818.
      View in: PubMed
    174. Hanauer SB. More food for thought. Nat Rev Gastroenterol Hepatol. 2009 May; 6(5):253. PMID: 19404262.
      View in: PubMed
    175. Hanauer SB. Outsourcing clinical trials. Nat Rev Gastroenterol Hepatol. 2009 Apr; 6(4):191. PMID: 19347005.
      View in: PubMed
    176. Pena Rossi C, Hanauer SB, Tomasevic R, Hunter JO, Shafran I, Graffner H. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol. 2009 Mar 20; 9:22. PMID: 19302707.
      View in: PubMed
    177. Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis. 2009 Sep; 3(3):162-7. PMID: 21172265.
      View in: PubMed
    178. Hanauer SB. A perfect storm. Nat Clin Pract Gastroenterol Hepatol. 2009 Mar; 6(3):127. PMID: 19259107.
      View in: PubMed
    179. Hanauer SB. Tyler, Faecalibacterium and biodiversity. Nat Clin Pract Gastroenterol Hepatol. 2009 Feb; 6(2):63. PMID: 19194380.
      View in: PubMed
    180. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009 Feb; 104(2):465-83; quiz 464, 484. PMID: 19174807.
      View in: PubMed
    181. Hanauer SB. Sarcopenia and the elusive fountain of youth. Nat Clin Pract Gastroenterol Hepatol. 2009 Jan; 6(1):1. PMID: 19127276.
      View in: PubMed
    182. Thia KT, Sandborn WJ, Lewis JD, Loftus EV, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease. Am J Gastroenterol. 2008 Dec; 103(12):3123-31. PMID: 18786111.
      View in: PubMed
    183. Hanauer SB. Biologic therapy for inflammatory bowel disease comes of age. Curr Gastroenterol Rep. 2008 Dec; 10(6):565-6. PMID: 19006611.
      View in: PubMed
    184. Hanauer SB. Early aggressive therapy for Crohn's disease. Curr Gastroenterol Rep. 2008 Dec; 10(6):566-7. PMID: 19006612.
      View in: PubMed
    185. Hanauer SB. Sitting on the fence. Nat Clin Pract Gastroenterol Hepatol. 2008 Dec; 5(12):655. PMID: 19039325.
      View in: PubMed
    186. Hanauer SB. Conflicts. Nat Clin Pract Gastroenterol Hepatol. 2008 Nov; 5(11):589. PMID: 18974750.
      View in: PubMed
    187. Hanauer SB. The ethics of phase I trials of biologic agents. Nat Clin Pract Gastroenterol Hepatol. 2008 Oct; 5(10):533. PMID: 18827830.
      View in: PubMed
    188. Perera MA, Thirumaran RK, Cox NJ, Hanauer S, Das S, Brimer-Cline C, Lamba V, Schuetz EG, Ratain MJ, Di Rienzo A. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J. 2009 Feb; 9(1):49-60. PMID: 18825162.
      View in: PubMed
    189. Hanauer SB. Modifying risk factors: do the means justify the ends? Nat Clin Pract Gastroenterol Hepatol. 2008 Sep; 5(9):475. PMID: 18758470.
      View in: PubMed
    190. Hanauer SB. Mea culpa. Nat Clin Pract Gastroenterol Hepatol. 2008 Aug; 5(8):409. PMID: 18670441.
      View in: PubMed
    191. Hanauer SB. Jet lag: life in the fast (and feast) lane. Nat Clin Pract Gastroenterol Hepatol. 2008 Jul; 5(7):349. PMID: 18596828.
      View in: PubMed
    192. Hanauer SB. Deadlines. Nat Clin Pract Gastroenterol Hepatol. 2008 Jun; 5(6):291. PMID: 18523481.
      View in: PubMed
    193. Hanauer SB. Flat polyps depress gastroenterologists. Nat Clin Pract Gastroenterol Hepatol. 2008 May; 5(5):231. PMID: 18446188.
      View in: PubMed
    194. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008 Aug; 135(2):400-9. PMID: 18602921.
      View in: PubMed
    195. Hanauer SB. An ounce of prevention. Nat Clin Pract Nephrol. 2008 Apr; 4(4):173. PMID: 18383614.
      View in: PubMed
    196. Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008 Mar; 27 Suppl 1:15-21. PMID: 18307645.
      View in: PubMed
    197. Hanauer SB. Experienced pleasantness. Nat Clin Pract Gastroenterol Hepatol. 2008 Mar; 5(3):119. PMID: 18317459.
      View in: PubMed
    198. Hanauer SB. Semantics. Nat Clin Pract Gastroenterol Hepatol. 2008 Feb; 5(2):59. PMID: 18253136.
      View in: PubMed
    199. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77. PMID: 18200659.
      View in: PubMed
    200. Hanauer SB. The role of loperamide in gastrointestinal disorders. Rev Gastroenterol Disord. 2008; 8(1):15-20. PMID: 18477966.
      View in: PubMed
    201. Hanauer SB. Subgroups. Nat Clin Pract Gastroenterol Hepatol. 2008 Jan; 5(1):1. PMID: 18174903.
      View in: PubMed
    202. Shah SB, Hanauer SB. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8(3):159-68. PMID: 18957923.
      View in: PubMed
    203. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008 Mar; 134(3):688-95. PMID: 18325386.
      View in: PubMed
    204. Hanauer SB. Biologic therapy for inflammatory bowel disease comes of age. Curr Gastroenterol Rep. 2007 Dec; 9(6):485-7. PMID: 18377800.
      View in: PubMed
    205. Hanauer SB. Immunosuppressive therapy in the formation of antibodies to infliximab in Crohn's disease. Curr Gastroenterol Rep. 2007 Dec; 9(6):487-8. PMID: 18377801.
      View in: PubMed
    206. Hanauer SB. My favorite topic...health. Nat Clin Pract Gastroenterol Hepatol. 2007 Dec; 4(12):641. PMID: 18043674.
      View in: PubMed
    207. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol. 2007 Dec; 21(12):827-34. PMID: 18080055.
      View in: PubMed
    208. Hanauer SB. An ounce of prevention. Nat Clin Pract Gastroenterol Hepatol. 2007 Nov; 4(11):583. PMID: 17978816.
      View in: PubMed
    209. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, Present D, Farraye FA, Wolf D, Sandborn WJ. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007 Oct; 13(10):1250-5. PMID: 17567869.
      View in: PubMed
    210. Hanauer SB. More likely than not. Nat Clin Pract Gastroenterol Hepatol. 2007 Sep; 4(9):469. PMID: 17768393.
      View in: PubMed
    211. Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut. 2007 Sep; 56(9):1181-3. PMID: 17698862.
      View in: PubMed
    212. Navarro FA, Hanauer SB, Kirschner BS. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007 Sep; 45(3):312-8. PMID: 17873743.
      View in: PubMed
    213. Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007 Nov; 133(5):1414-22. PMID: 17920064.
      View in: PubMed
    214. Hanauer SB. Parallel universes. Nat Clin Pract Gastroenterol Hepatol. 2007 Aug; 4(8):411. PMID: 17667991.
      View in: PubMed
    215. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007 Jul 19; 357(3):239-50. PMID: 17634459.
      View in: PubMed
    216. Hanauer SB. Where do our priorities lie? Nat Clin Pract Gastroenterol Hepatol. 2007 Jul; 4(7):353. PMID: 17607292.
      View in: PubMed
    217. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology. 2007 Jul; 133(1):312-39. PMID: 17631151.
      View in: PubMed
    218. Hanauer SB. Moving ahead or falling behind? Nat Clin Pract Gastroenterol Hepatol. 2007 Jun; 4(6):295. PMID: 17541443.
      View in: PubMed
    219. Hanauer SB, Wald A. Acute and chronic megacolon. Curr Treat Options Gastroenterol. 2007 Jun; 10(3):237-47. PMID: 17547862.
      View in: PubMed
    220. Hanauer SB, DuPont HL, Cooper KM, Laudadio C. Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin. 2007 May; 23(5):1033-43. PMID: 17519069.
      View in: PubMed
    221. Tuvlin JA, Raza SS, Bracamonte S, Julian C, Hanauer SB, Nicolae DL, King AC, Cho JH. Smoking and inflammatory bowel disease: trends in familial and sporadic cohorts. Inflamm Bowel Dis. 2007 May; 13(5):573-9. PMID: 17345609.
      View in: PubMed
    222. Hanauer SB. Uncertainty. Nat Clin Pract Gastroenterol Hepatol. 2007 May; 4(5):235. PMID: 17476206.
      View in: PubMed
    223. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19; 146(12):829-38. PMID: 17470824.
      View in: PubMed
    224. Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004. PMID: 17451704.
      View in: PubMed
    225. Hanauer SB. Balancing drug availability and patient safety. Nat Clin Pract Nephrol. 2007 Apr; 3(4):177. PMID: 17396284.
      View in: PubMed
    226. Hanauer SB. Back to basics: food for thought--and nutrition. Nat Clin Pract Gastroenterol Hepatol. 2007 Apr; 4(4):175. PMID: 17404585.
      View in: PubMed
    227. Litcher-Kelly L, Kellerman Q, Hanauer SB, Stone AA. Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel disease. Ann Behav Med. 2007 Apr; 33(2):207-12. PMID: 17447873.
      View in: PubMed
    228. Hanauer SB. Balancing drug availability and patient safety. Nat Clin Pract Gastroenterol Hepatol. 2007 Mar; 4(3):117. PMID: 17339848.
      View in: PubMed
    229. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol. 2007 Apr; 102(4):794-802. PMID: 17324131.
      View in: PubMed
    230. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007 Sep; 56(9):1232-9. PMID: 17299059.
      View in: PubMed
    231. Hanauer SB, Sandborn WJ. European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut. 2007 Feb; 56(2):161-3. PMID: 17303600.
      View in: PubMed
    232. Hanauer SB. Stepping up to good health. Nat Clin Pract Gastroenterol Hepatol. 2007 Feb; 4(2):59. PMID: 17268538.
      View in: PubMed
    233. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007 Feb; 5(2):209-14. PMID: 17296529.
      View in: PubMed
    234. Hanauer SB. Fragile egos. Nat Clin Pract Gastroenterol Hepatol. 2007 Jan; 4(1):1. PMID: 17203077.
      View in: PubMed
    235. Hanauer SB, Sandborn WJ. Refining the role of TNF antagonists for Crohn's disease. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S1-2. PMID: 17392632.
      View in: PubMed
    236. Hanauer SB. Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev Gastroenterol Disord. 2007; 7 Suppl 2:S17-22. PMID: 17392635.
      View in: PubMed
    237. Hanauer SB. The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S1-2. PMID: 18192960.
      View in: PubMed
    238. Shah SB, Hanauer SB. Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions. Rev Gastroenterol Disord. 2007; 7 Suppl 3:S3-10. PMID: 18192964.
      View in: PubMed
    239. Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007 Jan; 13(1):2-11. PMID: 17206633.
      View in: PubMed
    240. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb; 132(2):763-86. PMID: 17258735.
      View in: PubMed
    241. Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73. PMID: 17129812.
      View in: PubMed
    242. Hanauer SB. A generic problem. Nat Clin Pract Gastroenterol Hepatol. 2006 Dec; 3(12):649. PMID: 17130869.
      View in: PubMed
    243. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan; 132(1):52-65. PMID: 17241859.
      View in: PubMed
    244. Schreiber S, Keshavarzian A, Isaacs KL, Schollenberger J, Guzman JP, Orlandi C, Hanauer SB. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology. 2007 Jan; 132(1):76-86. PMID: 17241861.
      View in: PubMed
    245. Hanauer SB. Weighing in on obesity--a sample size issue? Nat Clin Pract Gastroenterol Hepatol. 2006 Nov; 3(11):593. PMID: 17068490.
      View in: PubMed
    246. Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50. PMID: 17059900.
      View in: PubMed
    247. Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006 Oct; 24 Suppl 3:37-40. PMID: 16961743.
      View in: PubMed
    248. Hanauer SB. Fertile ground. Nat Clin Pract Gastroenterol Hepatol. 2006 Oct; 3(10):533. PMID: 17008918.
      View in: PubMed
    249. Hanauer SB. "Hit me with your best shot... Fire away!". Nat Clin Pract Gastroenterol Hepatol. 2006 Sep; 3(9):473. PMID: 16951659.
      View in: PubMed
    250. Hanauer SB. Safety first: messages from Digestive Disease Week 2006. Nat Clin Pract Gastroenterol Hepatol. 2006 Aug; 3(8):415. PMID: 16883326.
      View in: PubMed
    251. Hanauer SB. It's right under our nose: homage to the Nobel Prize and other stories! Nat Clin Pract Gastroenterol Hepatol. 2006 Jul; 3(7):355. PMID: 16819477.
      View in: PubMed
    252. Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol. 2006 Jul; 40(6):482-9. PMID: 16825929.
      View in: PubMed
    253. Hanauer SB. Steroids as recreational drugs. Nat Clin Pract Gastroenterol Hepatol. 2006 Jun; 3(6):295. PMID: 16741529.
      View in: PubMed
    254. Hanauer SB. New lessons: classic treatments, expanding options in ulcerative colitis. Colorectal Dis. 2006 May; 8 Suppl 1:20-4. PMID: 16594960.
      View in: PubMed
    255. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006 May; 101(5):1030-8. PMID: 16606351.
      View in: PubMed
    256. Nguyen GC, Torres EA, Regueiro M, Bromfield G, Bitton A, Stempak J, Dassopoulos T, Schumm P, Gregory FJ, Griffiths AM, Hanauer SB, Hanson J, Harris ML, Kane SV, Orkwis HK, Lahaie R, Oliva-Hemker M, Pare P, Wild GE, Rioux JD, Yang H, Duerr RH, Cho JH, Steinhart AH, Brant SR, Silverberg MS. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006 May; 101(5):1012-23. PMID: 16696785.
      View in: PubMed
    257. Schölmerich J, Hanauer SB. Evidence-based medicine: applied science? Nat Clin Pract Gastroenterol Hepatol. 2006 Apr; 3(4):177. PMID: 16582938.
      View in: PubMed
    258. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006 Mar; 63(3):433-42; quiz 464. PMID: 16500392.
      View in: PubMed
    259. Hanauer SB. Procreation without recreation. Nat Clin Pract Gastroenterol Hepatol. 2006 Mar; 3(3):117. PMID: 16511528.
      View in: PubMed
    260. Achkar JP, Dassopoulos T, Silverberg MS, Tuvlin JA, Duerr RH, Brant SR, Siminovitch K, Reddy D, Datta LW, Bayless TM, Zhang L, Barmada MM, Rioux JD, Steinhart AH, McLeod RS, Griffiths AM, Cohen Z, Yang H, Bromfield GP, Schumm P, Hanauer SB, Cho JH, Nicolae DL. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am J Gastroenterol. 2006 Mar; 101(3):572-80. PMID: 16542294.
      View in: PubMed
    261. Hanauer SB. The 'tipping point' applied. Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):59. PMID: 16456553.
      View in: PubMed
    262. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006 Feb; 130(2):323-33; quiz 591. PMID: 16472588.
      View in: PubMed
    263. Hanauer SB, Sandborn WJ, Vakil N, Katz PO, Talley NJ, Rex DK, Hawes RH, Guda NM, Freeman ML, Keeffe EB, Balart LA. Best of DDW 2006. Rev Gastroenterol Disord. 2006; 6(3):153-89. PMID: 16957658.
      View in: PubMed
    264. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006 Jan; 12 Suppl 1:S3-9. PMID: 16378007.
      View in: PubMed
    265. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 08; 353(23):2462-76. PMID: 16339095.
      View in: PubMed
    266. Hanauer SB. I've sold my sport-utility vehicle. Nat Clin Pract Gastroenterol Hepatol. 2005 Dec; 2(12):551. PMID: 16327816.
      View in: PubMed
    267. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25. PMID: 16267322.
      View in: PubMed
    268. Sands BE, Abreu MT, Ferry GD, Griffiths AM, Hanauer SB, Isaacs KL, Lewis JD, Sandborn WJ, Steinhart AH. Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis. 2005 Nov; 11 Suppl 1:S22-8. PMID: 16254479.
      View in: PubMed
    269. Hanauer SB. Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol. 2005 Nov; 2(11):493. PMID: 16355136.
      View in: PubMed
    270. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005 Nov; 100(11):2478-85. PMID: 16279903.
      View in: PubMed
    271. Hanauer SB. Another one bites the dust. Nat Clin Pract Gastroenterol Hepatol. 2005 Oct; 2(10):435. PMID: 16224457.
      View in: PubMed
    272. Hanauer SB. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology. 2005 Oct; 129(4):1358-9; author reply 1359. PMID: 16230092.
      View in: PubMed
    273. Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, Cao D, Hanauer SB. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005 Sep 01; 22(5):441-6. PMID: 16128682.
      View in: PubMed
    274. Hanauer SB. Supplemental evidence. Nat Clin Pract Gastroenterol Hepatol. 2005 Sep; 2(9):375. PMID: 16265405.
      View in: PubMed
    275. Hanauer SB. Novel potential perils of volunteering for clinical trials. Nat Clin Pract Gastroenterol Hepatol. 2005 Aug; 2(8):337. PMID: 16265383.
      View in: PubMed
    276. Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005 Aug; 100(8):1780-7. PMID: 16086715.
      View in: PubMed
    277. Hanauer SB. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease. Am J Gastroenterol. 2005 Jul; 100(7):1438-9. PMID: 15984961.
      View in: PubMed
    278. Hanauer SB. Institutional review boards: the cost to academic medical centers. Nat Clin Pract Gastroenterol Hepatol. 2005 Jul; 2(7):287. PMID: 16265262.
      View in: PubMed
    279. Lim WC, Hanauer SB, Li YC. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jul; 2(7):308-15. PMID: 16265284.
      View in: PubMed
    280. Hanauer SB. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis. 2005 Jun; 11(6):609-12. PMID: 15905710.
      View in: PubMed
    281. Hanauer SB, Thisted RA. Treatment of Crohn's disease: the "long" of it. Gastroenterology. 2005 Jun; 128(7):2164-6. PMID: 15940649.
      View in: PubMed
    282. Hanauer SB. Obesity and visceral fat: a growing inflammatory disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):245. PMID: 16265208.
      View in: PubMed
    283. Ross AS, Gasparaitis A, Hurst R, Hanauer SB, Rubin DT. Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):281-5; quiz 1 p following 285. PMID: 16265232.
      View in: PubMed
    284. Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005 May-Jun; 39(5):390-5. PMID: 15815207.
      View in: PubMed
    285. Hanauer SB. Assessment, prevention and treatment of osteoporosis in inflammatory bowel disease patients: a bone of contention. Nat Clin Pract Gastroenterol Hepatol. 2005 May; 2(5):199. PMID: 16265185.
      View in: PubMed
    286. Hanauer SB. The 'upside' of travelers' diarrhea: a personal case report. Nat Clin Pract Gastroenterol Hepatol. 2005 Apr; 2(4):161. PMID: 16265160.
      View in: PubMed
    287. Kles KA, Vavricka SR, Turner JR, Musch MW, Hanauer SB, Chang EB. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflamm Bowel Dis. 2005 Mar; 11(3):253-7. PMID: 15735431.
      View in: PubMed
    288. Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):363-71. PMID: 15709986.
      View in: PubMed
    289. Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther. 2005 Feb 15; 21(4):373-84. PMID: 15709987.
      View in: PubMed
    290. Hanauer SB. The whole is greater than the sum. Nat Clin Pract Gastroenterol Hepatol. 2005 Feb; 2(2):59. PMID: 16265102.
      View in: PubMed
    291. Hanauer SB. Conflicts of interest. Nat Clin Pract Gastroenterol Hepatol. 2005 Jan; 2(1):1. PMID: 16265074.
      View in: PubMed
    292. Harrell LE, Rubin DT, Hanauer SB. Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):113-6; quiz 1 p following 116. PMID: 16265073.
      View in: PubMed
    293. Hanauer SB, Solomon J. Should you "just say 'no'"? Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):59. PMID: 16265046.
      View in: PubMed
    294. Hanauer SB. Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2004 Nov; 1(1):26-31. PMID: 16265041.
      View in: PubMed
    295. Hanauer SB, Sparrow M. COLAL-PRED Alizyme. Curr Opin Investig Drugs. 2004 Nov; 5(11):1192-7. PMID: 15573870.
      View in: PubMed
    296. Hanauer SB. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:60-5. PMID: 15352896.
      View in: PubMed
    297. Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004 Oct; 99(10):1984-9. PMID: 15447761.
      View in: PubMed
    298. Hanauer SB. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:97-101. PMID: 15352903.
      View in: PubMed
    299. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004 Sep; 127(3):723-9. PMID: 15362027.
      View in: PubMed
    300. Kane S, Kisiel J, Shih L, Hanauer S. HLA disparity determines disease activity through pregnancy in women with inflammatory bowel disease. Am J Gastroenterol. 2004 Aug; 99(8):1523-6. PMID: 15307871.
      View in: PubMed
    301. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004 Jul; 2(7):542-53. PMID: 15224278.
      View in: PubMed
    302. Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S2-10. PMID: 15475770.
      View in: PubMed
    303. Hanauer SB, Sparrow M. Therapy of ulcerative colitis. Curr Opin Gastroenterol. 2004 Jul; 20(4):345-50. PMID: 15703663.
      View in: PubMed
    304. Lichtenstein GR, Cuffari C, Kane SV, Hanauer S, Present DH. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S11-21. PMID: 15475769.
      View in: PubMed
    305. Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am. 2004 Jun; 33(2):303-17, ix-x. PMID: 15177540.
      View in: PubMed
    306. Sandborn WJ, Hanauer SB, Buch A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004 May 15; 19(10):1089-98. PMID: 15142198.
      View in: PubMed
    307. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology. 2004 May; 126(6):1582-92. PMID: 15168369.
      View in: PubMed
    308. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004 May; 2(5):379-88. PMID: 15118975.
      View in: PubMed
    309. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004 Feb; 126(2):402-13. PMID: 14762776.
      View in: PubMed
    310. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004 Jan; 99(1):91-6. PMID: 14687148.
      View in: PubMed
    311. Lim WC, Hanauer SB. Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(2):66-85. PMID: 15184826.
      View in: PubMed
    312. Lim WC, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(3):104-17. PMID: 15359211.
      View in: PubMed
    313. Hanauer SB. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004; 4 Suppl 3:S18-24. PMID: 15580149.
      View in: PubMed
    314. Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol. 2003 Dec; 98(12 Suppl):S18-23. PMID: 14697914.
      View in: PubMed
    315. Hanauer SB. Factoring in growth factors for treatment of inflammatory bowel disease. Curr Gastroenterol Rep. 2003 Dec; 5(6):485. PMID: 14602056.
      View in: PubMed
    316. Hanauer SB. Factoring in growth factors II. Curr Gastroenterol Rep. 2003 Dec; 5(6):486. PMID: 14602057.
      View in: PubMed
    317. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003 Nov; 125(5):1508-30. PMID: 14598268.
      View in: PubMed
    318. Chi KD, Hanauer SB. Benign solitary cecal ulcer: a case report and review of the literature. Dig Dis Sci. 2003 Nov; 48(11):2207-12. PMID: 14705829.
      View in: PubMed
    319. Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen D, Karban A, Dassopoulos T, Karaliukas R, Beaty TH, Hanauer SB, Duerr RH, Cho JH. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis. 2003 Sep; 9(5):281-9. PMID: 14555911.
      View in: PubMed
    320. Laine L, Hanauer SB. Considerations in the management of steroid-dependent Crohn's disease. Gastroenterology. 2003 Sep; 125(3):906-10. PMID: 12949734.
      View in: PubMed
    321. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003 Aug; 125(2):380-8. PMID: 12891539.
      View in: PubMed
    322. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003 Jun; 98(6):1309-14. PMID: 12818275.
      View in: PubMed
    323. Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 01; 17(11):1355-64. PMID: 12786629.
      View in: PubMed
    324. Hanauer SB. Immunogenicity of infliximab in Crohn's disease. N Engl J Med. 2003 May 22; 348(21):2155-6; author reply 2155-6. PMID: 12761378.
      View in: PubMed
    325. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003 May; 9(3):176-8. PMID: 12792223.
      View in: PubMed
    326. Hanauer SB. Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt. Am J Gastroenterol. 2003 Mar; 98(3):697-8. PMID: 12650813.
      View in: PubMed
    327. Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol. 2003 Feb; 17(1):131-7. PMID: 12617888.
      View in: PubMed
    328. Hanauer SB. Assessing the risk of lymphomas in inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(1):50-1. PMID: 12684594.
      View in: PubMed
    329. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003 Jan; 114(1):39-43. PMID: 12543288.
      View in: PubMed
    330. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3(2):81-92. PMID: 12776005.
      View in: PubMed
    331. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003 Jan; 17(1):29-42. PMID: 12492730.
      View in: PubMed
    332. Hanauer SB. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis. Am J Gastroenterol. 2003 Jan; 98(1):215-6. PMID: 12526968.
      View in: PubMed
    333. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002 Dec; 97(12):2962-72. PMID: 12492177.
      View in: PubMed
    334. Duerr RH, Barmada MM, Zhang L, Achkar JP, Cho JH, Hanauer SB, Brant SR, Bayless TM, Baldassano RN, Weeks DE. Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum Mol Genet. 2002 Oct 01; 11(21):2599-606. PMID: 12354785.
      View in: PubMed
    335. Hanauer SB. New steroids for IBD: progress report. Gut. 2002 Aug; 51(2):182-3. PMID: 12117876.
      View in: PubMed
    336. Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002 Jul; 97(7):1748-54. PMID: 12135030.
      View in: PubMed
    337. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 04; 359(9317):1541-9. PMID: 12047962.
      View in: PubMed
    338. Harrison J, Hanauer SB. Medical treatment of Crohn's disease. Gastroenterol Clin North Am. 2002 Mar; 31(1):167-84, x. PMID: 12122730.
      View in: PubMed
    339. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002 Feb; 122(2):512-30. PMID: 11832465.
      View in: PubMed
    340. Tytgat GN, Van Nueten L, Van De Velde I, Joslyn A, Hanauer SB. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002 Jan; 16(1):87-99. PMID: 11856082.
      View in: PubMed
    341. Vakil N, Hawes RH, Hanauer SB, Freeman ML, Camilleri M. Best of DDW 2002. Highlights from the 2002 Digestive Disease Week. May 19-22, 2002, San Francisco, CA. Rev Gastroenterol Disord. 2002; 2(3):126-41. PMID: 12227216.
      View in: PubMed
    342. Baron BW, Jeon HR, Glunz C, Peterson A, Cohen R, Hanauer S, Rubin D, Hart J, Baron JM. First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. J Clin Apher. 2002; 17(4):204-6. PMID: 12494414.
      View in: PubMed
    343. Hanauer SB. Can cyclosporine go it alone in severe ulcerative colitis? Curr Gastroenterol Rep. 2001 Dec; 3(6):455-6. PMID: 11696281.
      View in: PubMed
    344. Hanauer SB. The smoke is clearing in Crohn's disease. Curr Gastroenterol Rep. 2001 Dec; 3(6):456-7. PMID: 12953718.
      View in: PubMed
    345. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov; 121(5):1088-94. PMID: 11677200.
      View in: PubMed
    346. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001 Oct; 96(10):2929-33. PMID: 11693328.
      View in: PubMed
    347. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001 May 31; 411(6837):603-6. PMID: 11385577.
      View in: PubMed
    348. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001 May; 120(6):1330-8. PMID: 11313302.
      View in: PubMed
    349. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001 May; 7(2):83-8. PMID: 11383595.
      View in: PubMed
    350. Hanauer SB. Crohn's disease therapy: step up or top down therapy. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):189-90. PMID: 11475132.
      View in: PubMed
    351. Hanauer SB. Biologics in peri-operative management of Crohn's disease. Acta Gastroenterol Belg. 2001 Apr-Jun; 64(2):191-2. PMID: 11475133.
      View in: PubMed
    352. Ellman MH, Hanauer S, Sitrin M, Cohen R. Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol. 2001 Apr; 7(2):67-71. PMID: 17039097.
      View in: PubMed
    353. Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 2001 Mar; 96(3):635-43. PMID: 11280528.
      View in: PubMed
    354. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther. 2001 Jan; 15(1):35-44. PMID: 11136276.
      View in: PubMed
    355. Hanauer SB, Dassopoulos T. Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med. 2001; 52:299-318. PMID: 11160781.
      View in: PubMed
    356. Freeman ML, Hawes RH, Vakil N, Camilleri M, Hanauer SB. Best of DDW 2001. Highlights from the 2001 Digestive Disease Week. May 20-23, 2001, Atlanta, GA. Rev Gastroenterol Disord. 2001; 1(2):100-10. PMID: 12120175.
      View in: PubMed
    357. Hanauer SB. Update on medical management of inflammatory bowel disease: ulcerative colitis. Rev Gastroenterol Disord. 2001; 1(4):169-76. PMID: 12120183.
      View in: PubMed
    358. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000 Dec; 95(12):3469-77. PMID: 11151879.
      View in: PubMed
    359. Hanauer SB. Maintenance therapies for Crohn's disease: steroid dependence and delaying postoperative recurrence. Curr Gastroenterol Rep. 2000 Dec; 2(6):433. PMID: 11079042.
      View in: PubMed
    360. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJ, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1461-72. PMID: 11113067.
      View in: PubMed
    361. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000 Dec; 119(6):1473-82. PMID: 11113068.
      View in: PubMed
    362. Brant SR, Panhuysen CI, Bailey-Wilson JE, Rohal PM, Lee S, Mann J, Ravenhill G, Kirschner BS, Hanauer SB, Cho JH, Bayless TM. Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology. 2000 Dec; 119(6):1483-90. PMID: 11113069.
      View in: PubMed
    363. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000 Nov; 23(5):429-48. PMID: 11085348.
      View in: PubMed
    364. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2000 Nov; 95(11):3150-6. PMID: 11095334.
      View in: PubMed
    365. Michelassi F, Hurst RD, Melis M, Rubin M, Cohen R, Gasparitis A, Hanauer SB, Hart J. Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal study. Ann Surg. 2000 Sep; 232(3):401-8. PMID: 10973390.
      View in: PubMed
    366. Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000 Aug; 12(8):855-62. PMID: 10958212.
      View in: PubMed
    367. Hanauer SB. Medical therapy for ulcerative colitis. Curr Opin Gastroenterol. 2000 Jul; 16(4):324-8. PMID: 17031096.
      View in: PubMed
    368. Hanauer S, Good LI, Goodman MW, Pizinger RJ, Strum WB, Lyss C, Haber G, Williams CN, Robinson M. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000 Jul; 95(7):1749-54. PMID: 10925979.
      View in: PubMed
    369. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000 Jun 01; 342(22):1627-32. PMID: 10833208.
      View in: PubMed
    370. Cho JH, Nicolae DL, Ramos R, Fields CT, Rabenau K, Corradino S, Brant SR, Espinosa R, LeBeau M, Hanauer SB, Bodzin J, Bonen DK. Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum Mol Genet. 2000 May 22; 9(9):1425-32. PMID: 10814724.
      View in: PubMed
    371. Achkar JP, Hanauer SB. Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol. 2000 May; 95(5):1139-46. PMID: 10811318.
      View in: PubMed
    372. Cohen RD, Woseth DM, Thisted RA, Hanauer SB. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000 May; 95(5):1263-76. PMID: 10811338.
      View in: PubMed
    373. Hanauer SB. Surveying surveillance: are gastroenterologists consistently inconsistent, inconsistently consistent, or poorly educated? Gastrointest Endosc. 2000 Feb; 51(2):240-2. PMID: 10650283.
      View in: PubMed
    374. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000 Feb; 6(1):8-15. PMID: 10701144.
      View in: PubMed
    375. Hanauer SB. Evolutionary biologic therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 1999 Dec; 1(6):467-9. PMID: 10980987.
      View in: PubMed
    376. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec; 117(6):1271-7. PMID: 10579967.
      View in: PubMed
    377. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999 Oct; 117(4):761-9. PMID: 10500056.
      View in: PubMed
    378. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther. 1999 Sep; 13 Suppl 4:16-22; discussion 38. PMID: 10597335.
      View in: PubMed
    379. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, Hanauer SB, McDonald JW, Feagan BG, Fedorak RN, Isaacs KL, Pike MG, Mays DC, Lipsky JJ, Gordon S, Kleoudis CS, Murdock RH. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999 Sep; 117(3):527-35. PMID: 10464128.
      View in: PubMed
    380. Hanauer SB. Updating the approach to Crohn's disease. Hosp Pract (1995). 1999 Aug 15; 34(8):77-8, 81-3, 87-93; discussion 94. PMID: 10459364.
      View in: PubMed
    381. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology. 1999 Jul; 117(1):58-64. PMID: 10381910.
      View in: PubMed
    382. Hanauer SB. Medical therapy for Crohn's disease. Curr Opin Gastroenterol. 1999 Jul; 15(4):308-14. PMID: 17023963.
      View in: PubMed
    383. Stein RB, Hanauer SB. Medical therapy for inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun; 28(2):297-321. PMID: 10372270.
      View in: PubMed
    384. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999 Jun; 94(6):1587-92. PMID: 10364029.
      View in: PubMed
    385. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 06; 340(18):1398-405. PMID: 10228190.
      View in: PubMed
    386. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May; 5(2):119-33. PMID: 10338381.
      View in: PubMed
    387. Hanauer SB. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis. Gut. 1999 Apr; 44(4):455. PMID: 10075949.
      View in: PubMed
    388. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis. 1999 Feb; 5(1):1-10. PMID: 10028443.
      View in: PubMed
    389. Hanauer SB. No butts about it: put the fire out by lighting up. Inflamm Bowel Dis. 1998 Nov; 4(4):326; discussion 327. PMID: 9836087.
      View in: PubMed
    390. Brant SR, Fu Y, Fields CT, Baltazar R, Ravenhill G, Pickles MR, Rohal PM, Mann J, Kirschner BS, Jabs EW, Bayless TM, Hanauer SB, Cho JH. American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology. 1998 Nov; 115(5):1056-61. PMID: 9797357.
      View in: PubMed
    391. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol. 1998 Oct; 93(10):1867-72. PMID: 9772046.
      View in: PubMed
    392. Hanauer SB, Cohen RD, Becker RV, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998 Sep-Oct; 20(5):1009-28. PMID: 9829451.
      View in: PubMed
    393. Winter AM, Koeppen H, Hanauer SB. Non-Hodgkin's lymphoma presenting nine years after ileal-pouch ileoanal anastomosis for ulcerative colitis. Am J Gastroenterol. 1998 Sep; 93(9):1589-90. PMID: 9732957.
      View in: PubMed
    394. Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson LG, Walton-Bowen K, Haskell LP, Levine JG. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology. 1998 Sep; 115(3):525-32. PMID: 9721148.
      View in: PubMed
    395. Cho JH, Nicolae DL, Gold LH, Fields CT, LaBuda MC, Rohal PM, Pickles MR, Qin L, Fu Y, Mann JS, Kirschner BS, Jabs EW, Weber J, Hanauer SB, Bayless TM, Brant SR. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A. 1998 Jun 23; 95(13):7502-7. PMID: 9636179.
      View in: PubMed
    396. Stein RB, Hanauer SB. Medical management of Crohn's disease. Drugs Today (Barc). 1998 Jun; 34(6):541-8. PMID: 15010715.
      View in: PubMed
    397. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998 May; 4(2):79-83. PMID: 9589293.
      View in: PubMed
    398. Hanauer SB. How do I treat erythema nodosum, aphthous ulcerations, and pyoderma gangrenosum? Inflamm Bowel Dis. 1998 Feb; 4(1):70; discussion 73. PMID: 9552231.
      View in: PubMed
    399. Winter AM, Hanauer SB. Medical management of perianal Crohn's disease. Semin Gastrointest Dis. 1998 Jan; 9(1):10-4. PMID: 9547851.
      View in: PubMed
    400. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 09; 337(15):1029-35. PMID: 9321530.
      View in: PubMed
    401. Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol. 1997 Sep; 92(9):1424-8. PMID: 9317057.
      View in: PubMed
    402. Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A, Harig JM, Keshavarzian A, Robinson M, Sellin JH, Weinberg D, Vidican DE, Flemal KL, Rademaker AW. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut. 1997 Apr; 40(4):485-91. PMID: 9176076.
      View in: PubMed
    403. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol. 1997 Apr; 92(4):559-66. PMID: 9128300.
      View in: PubMed
    404. Roberts WG, Simon TJ, Berlin RG, Haggitt RC, Snyder ES, Stenson WF, Hanauer SB, Reagan JE, Cagliola A, Tanaka WK, Simon S, Berger ML. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology. 1997 Mar; 112(3):725-32. PMID: 9041233.
      View in: PubMed
    405. Cho JH, Fu Y, Kirschner BS, Hanauer SB. Confirmation of a susceptibility locus for Crohn's disease on chromosome 16. Inflamm Bowel Dis. 1997; 3(3):186-90. PMID: 23282803.
      View in: PubMed
    406. D'haens G, Baert F, Gasparaitis A, Hanauer S. Length and type of recurrent ileitis after ileal resection correlate with presurgical features in Crohn's disease. Inflamm Bowel Dis. 1997; 3(4):249-53. PMID: 23282870.
      View in: PubMed
    407. Sutherland LR, Hanauer S, Scholmerich J. Standards for trials of therapy in inflammatory bowel disease. Inflamm Bowel Dis. 1997; 3(4):277-83. PMID: 23282874.
      View in: PubMed
    408. Anderson R, Kaariainen IT, Hanauer SB. Protein-losing enteropathy and massive pulmonary embolism in a patient with giant inflammatory polyposis and quiescent ulcerative colitis. Am J Med. 1996 Sep; 101(3):323-5. PMID: 8873495.
      View in: PubMed
    409. Schlager SI, Hanauer SB. New Therapeutic Approaches to Peptic Ulcer Disease: The Role of Helicobacter Pylori. Am J Ther. 1996 Aug; 3(8):586-596. PMID: 11862295.
      View in: PubMed
    410. Roman-Unfer S, Bitran JD, Garrison L, Proeschel C, Hanauer S, Schroeder L, Johnson L, Klein L, Martinec J. A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells. Exp Hematol. 1996 Jun; 24(7):823-8. PMID: 8647233.
      View in: PubMed
    411. Hanauer SB. pANCA and classification resistance in ulcerative colitis. Mayo Clin Proc. 1996 May; 71(5):517-8. PMID: 8628035.
      View in: PubMed
    412. Cohen RD, Hanauer SB. Protection from primary sclerosing cholangitis: smoke trails of just coattails? Gastroenterology. 1996 May; 110(5):1658-62. PMID: 8613079.
      View in: PubMed
    413. Purl S, Johnson L, Hanauer S, Schroeder L, Proeschel C, Alberts J. Diphenhydramine provides relief of cyclophosphamide-related symptoms. Oncol Nurs Forum. 1996 Apr; 23(3):542. PMID: 8801517.
      View in: PubMed
    414. Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996 Mar 28; 334(13):841-8. PMID: 8596552.
      View in: PubMed
    415. Bitran JD, Samuels B, Klein L, Hanauer S, Johnson L, Martinec J, Harris E, Kempler J, White W. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant. 1996 Feb; 17(2):157-62. PMID: 8640160.
      View in: PubMed
    416. Elton E, Hanauer SB. Review article: the medical management of Crohn's disease. Aliment Pharmacol Ther. 1996 Feb; 10(1):1-22. PMID: 8871440.
      View in: PubMed
    417. Hanauer SB. Treatment of perianal Crohn's disease: a medical approach. Inflamm Bowel Dis. 1996; 2(1):64-6. PMID: 23282457.
      View in: PubMed
    418. Hanauer SB, Sutherland L. Little patients: big issues. Inflamm Bowel Dis. 1996; 2(2):121. PMID: 23282519.
      View in: PubMed
    419. Hanauer SB, Present DH, Murphy LK. Challenges in IBD Research: The Clinical Research Agenda. Inflamm Bowel Dis. 1996; 2(3):189-99. PMID: 23282564.
      View in: PubMed
    420. Campieri M, Gilat T, Hanauer S, Korelitz B, Lauritsen K, Malchow H, Martin F, Miglioli M, Modigliani R, Present D, Schölmerich J, Sutherland L. Drug Trials in Inflammatory Bowel Diseases 1993-1995: A Survey Conducted by the IOIBD. Inflamm Bowel Dis. 1996; 2(4):265-7. PMID: 23282593.
      View in: PubMed
    421. Sutherland LR, Hanauer SB. A registry of clinical trials. Inflamm Bowel Dis. 1996; 2(4):268. PMID: 23282594.
      View in: PubMed
    422. Cohen RD, Hanauer SB. Surveillance colonoscopy in ulcerative colitis: is the message loud and clear? Am J Gastroenterol. 1995 Dec; 90(12):2090-2. PMID: 8540493.
      View in: PubMed
    423. Fleshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum. 1995 Dec; 38(12):1241-5. PMID: 7497833.
      View in: PubMed
    424. Hanauer SB, Schulman MI. New therapeutic approaches. Gastroenterol Clin North Am. 1995 Sep; 24(3):523-40. PMID: 8809234.
      View in: PubMed
    425. Roman-Unfer S, Bitran JD, Hanauer S, Johnson L, Rita D, Booth C, Chen K. Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer. Bone Marrow Transplant. 1995 Jul; 16(1):163-8. PMID: 7581117.
      View in: PubMed
    426. Singleton JW, Hanauer S, Robinson M. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci. 1995 May; 40(5):931-5. PMID: 7729281.
      View in: PubMed
    427. D'Haens GR, Gasparaitis AE, Hanauer SB. Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease. Gut. 1995 May; 36(5):715-7. PMID: 7797122.
      View in: PubMed
    428. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995 Feb; 40(2):296-304. PMID: 7851193.
      View in: PubMed
    429. Hanauer SB, Baert FJ. The management of ulcerative colitis. Annu Rev Med. 1995; 46:497-505. PMID: 7598482.
      View in: PubMed
    430. Perman E, Hanauer S, Szeless S, Inoue K, Muts-Homsma S, Rahn S. International forum on ulcerative colitis. Risk selection aspects of ulcerative colitis. J Insur Med. 1995; 27(2):167-80. PMID: 15323085.
      View in: PubMed
    431. Campieri M, Goebell H, Hanauer S, Korelitz B, Lauritsen K, Malchow H, Martin F, Miglioli M, Modigliani R, Present D, Scholmerich J, Sutherland LR. Recommendations for New Trials of Currently Available Therapy by the IOIBD Task Force on Clinical Trials*. Inflamm Bowel Dis. 1995; 1(4):295-8. PMID: 23282431.
      View in: PubMed
    432. Hanauer SB, Baert F. Medical therapy of inflammatory bowel disease. Med Clin North Am. 1994 Nov; 78(6):1413-26. PMID: 7967917.
      View in: PubMed
    433. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 Jun 30; 330(26):1841-5. PMID: 8196726.
      View in: PubMed
    434. Silverstein MD, Lashner BA, Hanauer SB. Cigarette smoking and ulcerative colitis: a case-control study. Mayo Clin Proc. 1994 May; 69(5):425-9. PMID: 8170192.
      View in: PubMed
    435. Hanauer SB. Nicotine for colitis--the smoke has not yet cleared. N Engl J Med. 1994 Mar 24; 330(12):856-7. PMID: 8114839.
      View in: PubMed
    436. Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther. 1994 Feb; 8(1):27-34. PMID: 8186343.
      View in: PubMed
    437. Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol. 1993 Sep; 88(9):1343-51. PMID: 8362827.
      View in: PubMed
    438. Hanauer SB. Medical therapy of ulcerative colitis. Lancet. 1993 Aug 14; 342(8868):412-7. PMID: 8101907.
      View in: PubMed
    439. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993 Aug; 88(8):1188-97. PMID: 8338086.
      View in: PubMed
    440. D'Haens GR, Lashner BA, Hanauer SB. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am J Gastroenterol. 1993 Aug; 88(8):1174-8. PMID: 8338083.
      View in: PubMed
    441. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol. 1993 May; 88(5):646-9. PMID: 8480725.
      View in: PubMed
    442. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May; 104(5):1293-301. PMID: 8482443.
      View in: PubMed
    443. Lashner BA, Shaheen NJ, Hanauer SB, Kirschner BS. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol. 1993 Mar; 88(3):356-9. PMID: 8438840.
      View in: PubMed
    444. Block GE, Michelassi F, Tanaka M, Riddell RH, Hanauer SB. Crohn's disease. Curr Probl Surg. 1993 Feb; 30(2):173-265. PMID: 8458241.
      View in: PubMed
    445. Smith MB, Hanauer SB. Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med. 1992 Aug 13; 327(7):497-8. PMID: 1625744.
      View in: PubMed
    446. Hanauer S. Primary sclerosing cholangitis and ulcerative colitis: potential cofactors in the dysplasia sequence. Gastroenterology. 1992 Jun; 102(6):2161-2. PMID: 1587440.
      View in: PubMed
    447. Hanauer SB. Relief of functional bowel obstruction. JAMA. 1992 Jan 15; 267(3):414. PMID: 1727970.
      View in: PubMed
    448. Hanauer SB. Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath? Gastroenterology. 1991 Oct; 101(4):1130-1. PMID: 1679735.
      View in: PubMed
    449. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991 Sep; 32(9):1071-5. PMID: 1916494.
      View in: PubMed
    450. Lashner BA, Hanauer SB. The absence of an association between oral contraceptive use and ulcerative colitis in patients. Gastroenterology. 1991 Jun; 100(6):1784. PMID: 2019387.
      View in: PubMed
    451. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991 May-Jun; 6(3):192-219. PMID: 1676590.
      View in: PubMed
    452. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and ulcerative colitis. Gastroenterology. 1990 Oct; 99(4):1032-6. PMID: 2394326.
      View in: PubMed
    453. Hanauer SB. Aminosalicylates: old and new. Mt Sinai J Med. 1990 Oct; 57(5):283-7. PMID: 1982892.
      View in: PubMed
    454. Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol. 1990 Sep; 85(9):1083-7. PMID: 2389720.
      View in: PubMed
    455. Lashner BA, Hanauer SB, Silverstein MD. Testing nicotine gum for ulcerative colitis patients. Experience with single-patient trials. Dig Dis Sci. 1990 Jul; 35(7):827-32. PMID: 2194767.
      View in: PubMed
    456. Lashner BA, Turner BC, Bostwick DG, Frank PH, Hanauer SB. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci. 1990 Mar; 35(3):349-52. PMID: 2307080.
      View in: PubMed
    457. Hanauer SB. The role of mesalazine in Crohn's disease. Scand J Gastroenterol Suppl. 1990; 172:56-9. PMID: 1972296.
      View in: PubMed
    458. Hanauer SB. Inflammatory bowel disease revisited: newer drugs. Scand J Gastroenterol Suppl. 1990; 175:97-106. PMID: 1978406.
      View in: PubMed
    459. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study. Gastroenterology. 1989 Dec; 97(6):1442-7. PMID: 2583410.
      View in: PubMed
    460. Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci. 1989 Oct; 34(10):1536-41. PMID: 2791805.
      View in: PubMed
    461. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology. 1989 Aug; 97(2):255-9. PMID: 2568304.
      View in: PubMed
    462. Hanauer SB. 5-ASA enema therapy. Neth J Med. 1989 Jun; 35 Suppl 1:S11-20. PMID: 2702307.
      View in: PubMed
    463. Thor A, Itzkowitz SH, Schlom J, Kim YS, Hanauer S. Tumor-associated glycoprotein (TAG-72) expression in ulcerative colitis. Int J Cancer. 1989 May 15; 43(5):810-5. PMID: 2654025.
      View in: PubMed
    464. Lashner BA, Evans AA, Hanauer SB. Preoperative total parenteral nutrition for bowel resection in Crohn's disease. Dig Dis Sci. 1989 May; 34(5):741-6. PMID: 2496960.
      View in: PubMed
    465. Silverstein MD, Lashner BA, Hanauer SB, Evans AA, Kirsner JB. Cigarette smoking in Crohn's disease. Am J Gastroenterol. 1989 Jan; 84(1):31-3. PMID: 2912028.
      View in: PubMed
    466. Pamukcu R, Hanauer SB, Chang EB. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology. 1988 Oct; 95(4):975-81. PMID: 2842215.
      View in: PubMed
    467. Smith MB, Lashner BA, Hanauer SB. Smoking and inflammatory bowel disease in families. Am J Gastroenterol. 1988 Apr; 83(4):407-9. PMID: 3348193.
      View in: PubMed
    468. Hanauer SB. Fecal incontinence in the elderly. Hosp Pract (Off Ed). 1988 Mar 30; 23(3A):105-8, 111-2. PMID: 3127405.
      View in: PubMed
    469. Lashner BA, Hanauer SB, Silverstein MD. Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med. 1988 Feb; 108(2):274-8. PMID: 3124681.
      View in: PubMed
    470. Lashner BA, Evans AA, Kirsner JB, Hanauer SB. Prevalence and incidence of inflammatory bowel disease in family members. Gastroenterology. 1986 Dec; 91(6):1396-400. PMID: 3770366.
      View in: PubMed
    471. Lashner BA, Todorczuk J, Sahm DF, Hanauer SB. Clostridium difficile culture-positive toxin-negative diarrhea. Am J Gastroenterol. 1986 Oct; 81(10):940-3. PMID: 3766495.
      View in: PubMed
    472. Lashner BA, Kirsner JB, Hanauer SB. Acute pancreatitis associated with high-concentration lipid emulsion during total parenteral nutrition therapy for Crohn's disease. Gastroenterology. 1986 Apr; 90(4):1039-41. PMID: 3081397.
      View in: PubMed
    473. Bengoa JM, Hanauer SB, Sitrin MD, Baker AL, Rosenberg IH. Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology. 1985 Jan-Feb; 5(1):79-84. PMID: 3917969.
      View in: PubMed
    474. Kirsner JB, Hanauer SB. Crohn's disease. The problem and its management. Hosp Pract (Off Ed). 1984 Jul; 19(7):121-32, 135-6, 141-2. PMID: 6429165.
      View in: PubMed
    475. Kirsner JB, Deutsch S, Hanauer SB. Selected individual therapeutic problems in inflammatory bowel disease. Am J Gastroenterol. 1984 May; 79(5):368-75. PMID: 6144267.
      View in: PubMed
    476. Yuan SZ, Hanauer SB, Kluskens LF, Kraft SC. Circulating lymphocyte subpopulations in Crohn's disease. Gastroenterology. 1983 Dec; 85(6):1313-8. PMID: 6605274.
      View in: PubMed
    477. Hanauer SB, Wong KK, Frank PH, Sweet DL, Kirsner JB. Acute leukemia following inflammatory bowel disease. Dig Dis Sci. 1982 Jun; 27(6):545-8. PMID: 6953008.
      View in: PubMed
    478. Yung CW, Hanauer SB, Fretzin D, Rippon JW, Shapiro C, Gonzalez M. Disseminated Trichosporon beigelii (cutaneum). Cancer. 1981 Nov 01; 48(9):2107-11. PMID: 6945903.
      View in: PubMed
    479. Golomb HM, Hanauer SB. Infectious complications associated with hairy cell leukemia. J Infect Dis. 1981 May; 143(5):639-43. PMID: 7240806.
      View in: PubMed
    Hanauer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _